title: Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis.
abstract: The combination of traditional disease modifying antirheumatic drugs such as methotrexate (MTX) with biologic agents for treating rheumatoid arthritis (RA) has thus far been limited. The combination of MTX and a depleting anti-CD4 monoclonal antibody (cM-T412) has been evaluated in phase I and II trials in patients with refractory RA. The potential of combining MTX with other biologic agents is reviewed.
authors.affiliation: Department of Medicine, University of Alabama at Birmingham, AL, USA.
authors.forename: L W
authors.initials: LW
authors.lastname: Moreland
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D015704:CD4 Antigens / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D008727:Methotrexate / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D015704:CD4 Antigens; D008727:Methotrexate